Market News

Atea Reports Quarterly Loss, Provides Clinical Updates

Atea Pharmaceuticals (AVIR) has reported a wider-than-expected loss for the third quarter of 2021. Also, revenues missed analysts’ expectations. Despite the miss, shares of the clinical-stage biopharmaceutical company increased 3.1% in the extended trading session on Thursday. 

Results in Detail 

The company reported a loss of $0.34 per share against the Street’s loss estimate of $0.05 per share. It had reported a loss of $1.74 per share in the same quarter last year. 

Total collaboration revenues generated during the quarter stood at $32.8 million, which fell short of consensus estimates of $53.46 million. The company had reported nil collaboration revenue in the prior-year quarter. 

During the quarter, both general and administrative expenses and research and development expenses more than doubled on a year-over-year basis and stood at $11.9 million and $43 million, respectively.  (See Atea stock charts on TipRanks) 

Pipeline Update 

The CEO of Atea, Jean-Pierre Sommadossi, said, “New infectious virus data from a quantitative, highly-sensitive live virus assay further demonstrate AT-527’s antiviral response potential…These data support the findings from the Phase 2 trial conducted in hospitalized patients.” 

Sommadossi added, “In addition to the notable infectious virus data from the MOONSONG study, new in vitro data indicate that AT-511 (free base of AT-527) is active against variants of concern and/or of interest, including Delta. These results, combined with the protocol amendment we are planning, increase our confidence in a favorable outcome for our Phase 3 MORNINGSKY study. We are working expeditiously to submit the MORNINGSKY protocol amendment and are committed to developing and delivering AT-527 as an oral antiviral that will address treatment needs for patients as COVID-19 continues to evolve.” 

See Insiders’ Hot Stocks on TipRanks >> 

Wall Street’s Take  

The rest of the Street is cautiously optimistic about the stock and has a Moderate Buy consensus rating based on 2 Buys and 2 Holds. The average Atea price target of $15 implies 41% upside potential from current levels. Shares have lost 64% over the past year. 

Risk Analysis  

According to the new TipRanks’ Risk Factors tool, the Atea stock is at risk mainly from three factors: Tech and Innovation, Finance and Corporate, and Legal and Regulatory, which contribute 35%, 24%, and 18%, respectively, to the total 89 risks identified for the stock.

Related News: 
SoFi Books Lower-Than-Expected Q3 Loss; Shares Rise After-Hours 
Opendoor’s Q3 Results Beat Expectations; Shares Surge 
Lordstown Motors Collaborates with Foxconn; Shares Soar 21.2% 

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More